{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:54:08Z","timestamp":1785855248520,"version":"3.56.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bangrak STIs Center, Bangkok, Thailand"},{"name":"\u00d6rebro County Council Research Committee and Foundation for Medical Research at \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global public health concern, particularly due to increasing resistance to the last remaining monotherapy, ceftriaxone, in several Asian countries. We examined the AMR of gonococcal isolates obtained at the Bangrak STIs Center, Bangkok, Thailand in 2018\u201323, and used WGS on isolates resistant to ceftriaxone, cefixime and\/or azithromycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genital and extragenital swabs from males, females and transgender women were cultured. Etest (five antimicrobials) and EUCAST breakpoints (v16.0), or disc diffusion method (ciprofloxacin) were used to determine AMR. WGS was performed using Illumina NextSeq 550.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2018\u201323, 765 gonococcal isolates from 739 patients were cultured. Resistance to ceftriaxone, cefixime, azithromycin, tetracycline and ciprofloxacin was 0.5%, 0.8%, 1.7%, 83.7% and 95.7%, respectively. Ceftriaxone-resistant isolates, all resistant also to cefixime, were first detected in 2023 (n\u200a=\u200a3, 1.2%). Additional cefixime-resistant isolates were found in 2022 (n\u200a=\u200a2, 1.4%). Azithromycin-resistant isolates first emerged in 2020 (n\u200a=\u200a1, 0.9%) and increased to nine (3.7%) isolates in 2023. All ceftriaxone-resistant isolates contained penA-60.001, but cefixime resistance was additionally caused by penA-34.019 and penA-10.001. All azithromycin-resistant isolates had 23S rRNA mutations and\/or mosaic\/semi-mosaic MtrD (subunit of the MtrCDE efflux pump).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Resistance to ceftriaxone, cefixime and azithromycin has emerged in gonococcal strains circulating in Bangkok, Thailand, and resistance appears to be increasing. Resistance to these last options for monotherapy or dual therapy emphasize the need for strengthened national culture-based and genomic surveillance to prevent the spread of MDR and XDR strains in Thailand and globally, and implementation of the novel oral treatments, i.e. zoliflodacin and gepotidacin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag260","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:42:55Z","timestamp":1784288575000},"source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial resistance in\n                    <i>Neisseria gonorrhoeae<\/i>\n                    isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018\u201323"],"prefix":"10.1093","volume":"81","author":[{"given":"Porntip","family":"Paopang","sequence":"first","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongsathorn","family":"Sangprasert","sequence":"additional","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Golparian","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-2108","authenticated-orcid":false,"given":"Natnaree","family":"Girdthep","sequence":"additional","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutchaya","family":"Jintana","sequence":"additional","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supawadee","family":"Sonnak","sequence":"additional","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padchara","family":"Sangsuk","sequence":"additional","affiliation":[{"name":"Department of Medical Technology and Clinical Pathology, Vachira Phuket Hospital , Phuket ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thewarkrith","family":"Bunpan","sequence":"additional","affiliation":[{"name":"Department of Medical Technology and Clinical Pathology, Vachira Phuket Hospital , Phuket ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-2081","authenticated-orcid":false,"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]},{"name":"Institute for Global Health, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-7776","authenticated-orcid":false,"given":"Rossaphorn","family":"Kittiyaowamarn","sequence":"additional","affiliation":[{"name":"Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026080410192097500_dkag260-B1","author":"World Health Organization"},{"key":"2026080410192097500_dkag260-B2","author":"HUB HIV INFO"},{"key":"2026080410192097500_dkag260-B3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026080410192097500_dkag260-B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101181","article-title":"WHO global gonococcal antimicrobial surveillance programmes, 2019-22: a retrospective observational study","volume":"6","author":"Unemo","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026080410192097500_dkag260-B5","author":"World Health Organization"},{"key":"2026080410192097500_dkag260-B6","author":"World Health Organization"},{"key":"2026080410192097500_dkag260-B7","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","author":"Unemo","journal-title":"Int J STD AIDS"},{"key":"2026080410192097500_dkag260-B8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/09564624251345195","article-title":"British Association of Sexual Health and HIV UK National Guideline for the Management of Infection with Neisseria gonorrhoeae, 2025","volume":"36","author":"Fifer","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026080410192097500_dkag260-B9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC's treatment guidelines for gonococcal infection, 2020","volume":"69","author":"Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026080410192097500_dkag260-B10","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae053","article-title":"High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)","volume":"6","author":"Ouk","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026080410192097500_dkag260-B11","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S1473-3099(23)00479-6","article-title":"The Enhanced Gonococcal Surveillance Programme, Cambodia","volume":"23","author":"Ouk","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026080410192097500_dkag260-B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101125","article-title":"The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023","volume":"48","author":"Lan","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026080410192097500_dkag260-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101709","article-title":"The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024","volume":"63","author":"Lan","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"2026080410192097500_dkag260-B14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7312a2","article-title":"Ceftriaxone-resistant gonorrhea\u2014China, 2022","volume":"73","author":"Zhu","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026080410192097500_dkag260-B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IM9.0000000000000113","article-title":"Global transmission of the penA allele 60.001\u2013containing high-level ceftriaxone-resistant gonococcal FC428 clone and antimicrobial therapy of associated cases: a review","volume":"5","author":"van der Veen","year":"2023","journal-title":"Infect Microbe Dis"},{"key":"2026080410192097500_dkag260-B16","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2579397","article-title":"Emergence, evolution and temporal spread of ceftriaxone-resistant Neisseria gonorrhoeae in China from 2002 to 2022: a retrospective genomic surveillance study","volume":"14","author":"Zhang","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"2026080410192097500_dkag260-B17","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1128\/AAC.00504-16","article-title":"New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan","volume":"60","author":"Nakayama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080410192097500_dkag260-B18","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"2026080410192097500_dkag260-B19","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B20","doi-asserted-by":"publisher","DOI":"10.1128\/mra.01231-23","article-title":"Complete reference genomes of two ceftriaxone-resistant Neisseria gonorrhoeae strains identified in routine surveillance in Bangkok, Thailand, using Nanopore Q20+ chemistry, VolTRAX V2b, and Illumina sequencing","volume":"13","author":"Sangprasert","year":"2024","journal-title":"Microbiol Resour Announc"},{"key":"2026080410192097500_dkag260-B21","author":"World Health Organization"},{"key":"2026080410192097500_dkag260-B22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1473-3099(18)30225-1","article-title":"Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey","volume":"18","author":"Harris","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026080410192097500_dkag260-B23","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S2666-5247(22)00044-1","article-title":"Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study","volume":"3","author":"S\u00e1nchez-Bus\u00f3","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026080410192097500_dkag260-B24","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S2666-5247(23)00370-1","article-title":"Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study","volume":"5","author":"Golparian","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026080410192097500_dkag260-B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101663","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study","volume":"61","author":"Maatouk","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"2026080410192097500_dkag260-B26","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad139","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility trends in Bangkok, Thailand, 2015-21: Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)","volume":"5","author":"Kittiyaowamarn","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2026080410192097500_dkag260-B27","volume-title":"Guidelines of Sexually Transmitted Diseases Treatment 2015 Thailand","author":"Kongkergkiat","year":"2015","edition":"1st edn"},{"key":"2026080410192097500_dkag260-B28","volume-title":"Guideline of Gonorrhea Management 2019 Thailand","author":"Kittiyaowamarn","year":"2019","edition":"1st edn"},{"key":"2026080410192097500_dkag260-B29","volume-title":"Manual of Medical Laboratory Investigation for Gonorrhea Thailand","author":"Kittiyaowamarn","year":"2020","edition":"1st edn"},{"key":"2026080410192097500_dkag260-B30","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkae176","article-title":"The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains\u2014phenotypic, genetic and reference genome characterization","volume":"79","author":"Unemo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"2026080410192097500_dkag260-B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101270","article-title":"Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study","volume":"7","author":"Unemo","year":"2026","journal-title":"Lancet Microbe"},{"key":"2026080410192097500_dkag260-B33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/jac\/dkac366","article-title":"GyrB in silico mining in 27151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility","volume":"78","author":"Golparian","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B34","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"2026080410192097500_dkag260-B35","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080410192097500_dkag260-B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2025.100624","article-title":"High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024","volume":"15","author":"Jacobsson","year":"2025","journal-title":"IJID Reg"},{"key":"2026080410192097500_dkag260-B38","author":"Golparian"},{"key":"2026080410192097500_dkag260-B39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3201\/eid3206.251860","article-title":"Emergence of ceftriaxone-resistant Neisseria gonorrhoeae penA-60-carrying strains, Thailand, 2025","volume":"32","author":"Kittiyaowamarn","year":"2026","journal-title":"Emerg Infect Dis"},{"key":"2026080410192097500_dkag260-B40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/antibiotics10020137","article-title":"Antibiotics\u2019 use in Thailand: community pharmacists\u2019 knowledge, attitudes and practices","volume":"10","author":"Siltrakool","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026080410192097500_dkag260-B41","author":"Division of AIDS and STIs, Department of Disease Control, Ministry of Public Health, Thailand"},{"key":"2026080410192097500_dkag260-B42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jac\/dkae063","article-title":"Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea","volume":"79","author":"Unemo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B43","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf452","article-title":"High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24","volume":"81","author":"Ahlstrand","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"2026080410192097500_dkag260-B44","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkag001","article-title":"In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates","volume":"81","author":"Cole","year":"2026","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag260\/70479842\/dkag260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag260\/70479842\/dkag260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:32:34Z","timestamp":1785853954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag260\/8751059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag260","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag260"}}